1353P - The overall incidence and pattern of chemotherapy-induced nausea and vomiting (CINV) in carboplatin is similar to those of cisplatin and should be...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Complications/Toxicities of Treatment
Supportive and Palliative Care
Biological Therapy
Presenter Kazuo Tamura
Citation Annals of Oncology (2014) 25 (suppl_4): iv471-iv477. 10.1093/annonc/mdu350
Authors K. Tamura1, K. Aiba2, T. Saeki3, M. Shimokawa4, K. Hirata5, Y. Maehara6, M. Kitajima7
  • 1Medical Oncology, Fukuoka University, 814-0180 - Fukuoka/JP
  • 2Medical Oncology, Jikei Medical School, Tokyo/JP
  • 3Breast Oncology, Saitama Medical UniversityInternatl Medical Centre, Saitama/JP
  • 4Clinical Research, kyushu Cancer Center, Fukuoka/JP
  • 5Department Of Surgery, Surgical Oncology And Science, Sapporo Medical University School of Medicine, Sapporo/JP
  • 6Surgery And Science, kyushu University, Fukuoka/JP
  • 7Director, International University of Health and Welfare, Ohtawara/JP



We have reported the risk factors of CINV by the CINV study in Japan (ESMO 2013). Since the incidence and pattern of CINV other than those of cisplatin-based regimen (CDDP) have not been clearly determined, we investigated those induced by carboplatin-based regimen (CBDCA) to compare with CDDP.


Between May 2011 and December 2012, 2068 patients who received systemic chemotherapy with highly (HEC) or moderately emetogenic agents (MEC) were registered. A total of 1910 was evaluable and 1091 patients treated with either CDDP or CBDCA were analyzed. According to the guideline, 2 antiemetics with dexamethasone and 5-HT3-receptor antagonist were recommended for CBDCA, while 3 antiemetics with above 2 antiemetics + NK1- receptor antagonist were recommended for CDDP and optionally CBDCA. Occurrence and severity of CINV were assessed with a 7-days diary recorded by the patients.


The median age of CDDP was 64 (range: 25-85) with 451 males and 208 females. The median age of CBDCA was also 64 (range: 30-85) with 194 males and 238 females. The incidence of acute vomiting was 2.3% and 1.2% in CDDP and CBDCA, respectively, while that of delayed vomiting was 11.8% and 18.1%. Similarly, the incidence of acute nausea was 8.5% and 5.8% in CDDP and CBDCA respectively, while that of delayed nausea was 46.7% and 43.3%. The pattern of persistent nausea from day 3 to 7 by CBDCA appeared to be similar to that of CDDP. Multivariate analysis by using CINV risk factors (age, motion and morning sickness, drinking habit, primary site, hemoglobin, albumin, regimen, antiemetics) was performed separately by gender. The incidence of delayed nausea in males was higher in CDDP than that of CBDCA (odds ratio, OR: 1.449, 95%CI: 1.012-2.075), while in females, the history of morning sickness induced delayed nausea and vomiting significantly (OR: 2.075 and 2.073, 95%CI: 1.380-3.119 and 1.294-3.321, respectively) and 3 antiemetics could control delayed vomiting better than 2 antiemetics (OR: 0.339, 95%CI: 0.245-0.647). Drinking habits in males and higher age in both sex had low OR for delayed nausea.


The overall incidence and pattern of CINV is similar in both CDDP and CBDCA. In the present antiemetic era, CBDCA should be considered HEC and 3 antiemetics are recommended especially in women.


All authors have declared no conflicts of interest.